BioInno
Empowering global biopharma with world-class cell culture and GMP production services.
Empowering global biopharma with world-class cell culture and GMP production services.
BioInno is a China-based startup that aims to empower global biopharma with world-class cell culture and GMP production services. Established in 2019, BioInno offers comprehensive biopharmaceutical CDMO services and cell culture media, specializing in process development and GMP production. The company is focused on supporting businesses in bringing protein, cell therapy, and gene therapy drugs to both Chinese and global markets. In its latest milestone, BioInno secured a Series A investment on 21st December 2021. The investment was led by a consortium of investors including EFung Capital, 深圳市道合科技投资管理有限公司, Yuanqi Capital, Guoxin Investment, Yifeng Capital, Tigermed, and TaiKun Fund. With its expertise in the Biopharma, Biotechnology, and Pharmaceutical industries, BioInno stands poised to make a significant impact in the global biopharmaceutical landscape.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series A | Unknown | 7 |
|
21 Dec 2021 |
No recent news or press coverage available for BioInno.
We care about your data, and we'd love to use cookies make your experience better.